A Randomized, Double-Blind, Placebo Controlled Phase II, Multi-Centre, Study of the Efficacy and Safety of CT 327, a Topical Cream Formulation of Pegylated K252a, When Administered Twice Daily for Eight Weeks to Patients With Mild to Moderate Psoriasis Vulgaris.

Trial Profile

A Randomized, Double-Blind, Placebo Controlled Phase II, Multi-Centre, Study of the Efficacy and Safety of CT 327, a Topical Cream Formulation of Pegylated K252a, When Administered Twice Daily for Eight Weeks to Patients With Mild to Moderate Psoriasis Vulgaris.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2012

At a glance

  • Drugs SNA 120 (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jul 2011 New source identified (European Clinical Trials Database).
    • 09 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Feb 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top